These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 19820956)

  • 21. α-Synuclein Heteromers in Red Blood Cells of Alzheimer's Disease and Lewy Body Dementia Patients.
    Daniele S; Baldacci F; Piccarducci R; Palermo G; Giampietri L; Manca ML; Pietrobono D; Frosini D; Nicoletti V; Tognoni G; Giorgi FS; Lo Gerfo A; Petrozzi L; Cavallini C; Franzoni F; Ceravolo R; Siciliano G; Trincavelli ML; Martini C; Bonuccelli U
    J Alzheimers Dis; 2021; 80(2):885-893. PubMed ID: 33579836
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Pathological and clinical comparison of Parkinson’s disease dementia and dementia with Lewy bodies].
    Bencs V; Bencze J; Módis VL; Simon V; Kálmán J; Hortobágyi T
    Orv Hetil; 2020 May; 161(18):727-737. PubMed ID: 32338488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
    Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
    Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High discriminatory ability of peripheral and CFSF biomarkers in Lewy body diseases.
    Bougea A; Stefanis L; Emmanouilidou E; Vekrelis K; Kapaki E
    J Neural Transm (Vienna); 2020 Mar; 127(3):311-322. PubMed ID: 31912280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases.
    Duka V; Lee JH; Credle J; Wills J; Oaks A; Smolinsky C; Shah K; Mash DC; Masliah E; Sidhu A
    PLoS One; 2013; 8(9):e75025. PubMed ID: 24073234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Significance of brain lesions in Parkinson disease dementia and Lewy body dementia.
    Jellinger KA
    Front Neurol Neurosci; 2009; 24():114-125. PubMed ID: 19182469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropathology of Parkinson's disease dementia and dementia with Lewy bodies with reference to striatal pathology.
    Tsuboi Y; Uchikado H; Dickson DW
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S221-4. PubMed ID: 18267239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease dementia: what's in a Lewy body?
    Burn DJ
    J Neural Transm Suppl; 2006; (70):361-5. PubMed ID: 17017554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hippocampal CA2 Lewy pathology is associated with cholinergic degeneration in Parkinson's disease with cognitive decline.
    Liu AKL; Chau TW; Lim EJ; Ahmed I; Chang RC; Kalaitzakis ME; Graeber MB; Gentleman SM; Pearce RKB
    Acta Neuropathol Commun; 2019 Apr; 7(1):61. PubMed ID: 31023342
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders.
    Coughlin D; Xie SX; Liang M; Williams A; Peterson C; Weintraub D; McMillan CT; Wolk DA; Akhtar RS; Hurtig HI; Branch Coslett H; Hamilton RH; Siderowf AD; Duda JE; Rascovsky K; Lee EB; Lee VM; Grossman M; Trojanowski JQ; Irwin DJ
    Ann Neurol; 2019 Feb; 85(2):259-271. PubMed ID: 30549331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia.
    Vallortigara J; Whitfield D; Quelch W; Alghamdi A; Howlett D; Hortobágyi T; Johnson M; Attems J; O'Brien JT; Thomas A; Ballard CG; Aarsland D; Francis PT
    J Alzheimers Dis; 2016; 50(1):101-10. PubMed ID: 26639969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies.
    Muntané G; Dalfó E; Martinez A; Ferrer I
    Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Associations Between APOE Variants, Tau and α-Synuclein.
    Rodriguez-Vieitez E; Nielsen HM
    Adv Exp Med Biol; 2019; 1184():177-186. PubMed ID: 32096038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential insular cortex subregional vulnerability to α-synuclein pathology in Parkinson's disease and dementia with Lewy bodies.
    Fathy YY; Jonker AJ; Oudejans E; de Jong FJJ; van Dam AW; Rozemuller AJM; van de Berg WDJ
    Neuropathol Appl Neurobiol; 2019 Apr; 45(3):262-277. PubMed ID: 29797340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuropathology of dementia in a large cohort of patients with Parkinson's disease.
    Horvath J; Herrmann FR; Burkhard PR; Bouras C; Kövari E
    Parkinsonism Relat Disord; 2013 Oct; 19(10):864-8; discussion 864. PubMed ID: 23746454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biochemical and pathological correlates of cognitive and behavioural change in DLB/PDD.
    Francis PT
    J Neurol; 2009 Aug; 256 Suppl 3():280-5. PubMed ID: 19711117
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
    Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
    Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The structural differences between patient-derived α-synuclein strains dictate characteristics of Parkinson's disease, multiple system atrophy and dementia with Lewy bodies.
    Van der Perren A; Gelders G; Fenyi A; Bousset L; Brito F; Peelaerts W; Van den Haute C; Gentleman S; Melki R; Baekelandt V
    Acta Neuropathol; 2020 Jun; 139(6):977-1000. PubMed ID: 32356200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.